Early Diastolic Release Flow Is a Sensitive Early Marker for Left Ventricular Apical Aneurysm in Patients with

Syed Bukhari1, Ali Asghar Kassamali1, Henry Pronovost1

  • 1Johns Hopkins University, Division of Cardiology, Baltimore, Maryland, USA.

CJC Open
|March 16, 2026
PubMed

Insights

Early-diastolic release flow (EDRF) is a sensitive echocardiographic marker for left ventricular apical aneurysm (LVAA) in hypertrophic cardiomyopathy (HCM). EDRF aids in detecting LVAA missed by standard 2D echocardiography, prompting further investigation.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Echocardiography

Background:

  • Left ventricular apical aneurysm (LVAA) is a rare complication of hypertrophic cardiomyopathy (HCM).
  • LVAA is linked to increased risks of ventricular arrhythmia and thromboembolism.
  • Standard 2D echocardiography has limitations in detecting LVAA.

Purpose of the Study:

  • To evaluate early-diastolic release flow (EDRF) as a sensitive echocardiographic marker for LVAA in HCM patients.
  • To compare the sensitivity of EDRF with standard 2D echocardiography for LVAA detection.
  • To assess changes in LVAA and EDRF over a 5-year period.

Main Methods:

  • Retrospective analysis of echocardiographic studies in 51 HCM patients with LVAA.
  • Assessment for EDRF, defined as basally-directed flow in early diastole.
  • Comparison of EDRF sensitivity against other imaging modalities and longitudinal assessment of aneurysm size and EDRF.

Main Results:

  • EDRF detected LVAA in 90% of patients (46/51), significantly higher than 2D echocardiography (49%, 25/51).
  • EDRF sensitivity was 100% in cases missed by 2D echocardiography (26/26).
  • Over 5 years, LVAA size increased and LVEF decreased; EDRF visualization was lost in 25% of patients.

Conclusions:

  • EDRF is a highly sensitive echocardiographic marker for LVAA in HCM.
  • EDRF is particularly valuable for identifying LVAA missed by standard 2D echocardiography.
  • Identification of EDRF should prompt further diagnostic imaging, such as CMR or contrast-enhanced echocardiography.
Abstract

Related Concept Videos

Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
794
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
627
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K